Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12357446 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL14110948 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2CHRM2CHRM1CHRM3GRM5 | |
| SCHEMBL18711900 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL17572004 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL20690443 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL25097073 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL27139 | 0.76 | RECQL (0.32) | CHRM2CHRM1CHRM3CHRM4RECQL | |
| SCHEMBL23309153 | 0.75 | CHRM2 (0.37) | CHRM2CHRM1CHRM3RECQLMAPK1 | |
| SCHEMBL17572101 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2GRM5 | |
| SCHEMBL23245840 | 0.75 | CHRM2 (0.55) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | SMN1; SMN2 3541/4885CHRM2 3041/4885CHRM1 2261/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | SMN1; SMN2 2887/4885CHRM2 2944/4885CHRM1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.